Evaluation of pleural effusion sCD26 and DPP-IV as diagnostic biomarkers in lung disease by Sánchez Otero, Nuria et al.
Evaluation of pleural effusion sCD26 and
DPP-IV as diagnostic biomarkers in lung
disease
Nuria Sánchez-Otero1, Francisco Javier Rodrı́guez-Berrocal1, Marı́a Páez de la Cadena1,
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In this study, we measured ADA and DPP-IV enzymatic activity and sCD26 concentration in 150 pleural
effusion (PE) samples and tested for correlations between these and other cellular and biochemical
measures. We found that DPP-IV in particular might improve the specificity (but not the sensitivity) of the
ADA test for diagnosis of pulmonary tuberculosis, since half of the false ADA positive results in
non-tuberculous PE were also DPP-IV positive. A percentage of patients with malignant PE were sCD26 or
DPP-IV positive; however, some patients with benign PE also tested positive. As a pattern associated with
DPP-IV (but not the CD26 protein) was observed in PE, we searched for a finding that might increase the
value of these biomarkers for diagnosis of malignancy. The observed pattern was related to the presence of
leukocytes, as indicated by correlations with the cell count, and to a band of 180 kDa, detected by
immunoblotting.
T
he soluble form of CD26 (sCD26), ascribed to the DPP-4 gene and originating from shedding of the
transmembrane protein, is found in many biological fluids. The physiological role of sCD26 and its relation,
if any, to CD26 functions remain poorly understood1. Dipeptidyl peptidase IV (DPP-IV), a serine protease
belonging to type II transmembrane glycoproteins (EC 3.4.14.5), is expressed on the surface of epithelial cells of
diverse tissues, on endothelial cells of blood vessels and on some immune cells such as T lymphocytes, B
lymphocytes and NK cells. By cleaving dipeptides from the N-terminal end of peptides and polypeptides with
proline or alanine in the second position, DPP-IV controls the activity of many bioactive molecules, including
cytokines and chemokines, incretins and gastrointestinal hormones, vasoactive peptides and neuropeptides2–4.
DPP-IV is a multifunctional regulatory biomolecule, and in addition to its enzymatic activity, it interacts with
many plasma membrane proteins, such as ADA and the chemokine receptor CXCR4, and with extracellular
matrix components such as collagen. Thus, DPP-IV is involved in diverse biological processes apart from protein
degradation in the gut, especially immune functions and inflammation2,4, and it has also become a novel thera-
peutic target for inhibitors that extend endogenously produced insulin half-life in diabetics1.
Pleural effusion (the pathological accumulation of fluid in the pleural cavity that surrounds the lung) may
appear as the result of different benign abnormalities, which are often caused by tuberculosis (TB), or as the result
of malignant disease5. Tuberculous pleural effusion (TPE), which is considered a form of extrapulmonary TB,
remained a diagnostic challenge for clinicians until the identification of molecular biomarkers that yielded a rapid
and accurate diagnosis of tuberculous pleuritis6,7. Among the best-established techniques, determination of
adenosine deaminase (ADA) activity and the concentration of cytokine IFN-gamma in the pleural effusion are
included in the supplemental diagnostic index for pleural tuberculosis8–10. However, none of the available tests for
TPE are wholly accurate10,11, and any biomarker that can increase their reliability in indicating whether anti-
tuberculosis therapy should be resumed or discontinued will be valuable.
Interest has recently been shown in determining sCD26 concentration and DPP-IV acativity in PE, for two
reasons. First, the plasma membrane CD26 was previously known as ADA complexing or binding protein (ADA-
CP or ADA-BP)1,12, although the ADA of most diagnostic importance in biological fluids (including TPE) is
ADA2, the isoenzyme that is produced by monocytes and that predominates in the sera of normal individuals.
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soluble ADA-CP (sCD26). Extracellular ADA is probably involved
in the control of adenosine-mediated signalling through purinergic
receptors, at least in leukocytes13,14.
The second reason for studying sCD26/DPP-IV is that tuberculous
infections generate Th1-like immune responses, such as IFN-gamma
secretion. Membrane-bound expression of soluble CD26 correlated
with Th1-like responses including cytokine production15–17.
Previous studies have shown that measurement of DPP-IV activ-
ity18 and sCD26 concentration19,20 slightly improved the already high
sensitivity and diagnostic efficiency of the ADA test for tuberculous
pleurisy. However, as shown in some diseases1, and even in healthy
donor serum samples, enzymatic activity and enzyme concentrations
are not closely correlated. We therefore determined the sCD26 con-
centration and DPP-IV and ADA activity in the same samples to
investigate this hypothesis in relation to PE. We included PE assoc-
iated with malignant pathologies (mainly lung cancer)20 in the study,
partly to widen the cohort of the study and also because many recent
studies have demonstrated an important role for DPPIV/CD26 (both
altered cell surface CD26 expression as well as changes in serum
DPP-IV activity) in the initial steps of malignant transformation,
in progression of the tumour and in the metastatic process2–4,21–24.
Therefore, any information regarding the role of these molecules in
PE will be important for developing diagnostic tests or treatments.
Results
Basic demographic parameters of ADA and DPP-IV activity and
sCD26 concentration in PE samples from patients with benign
and malignant pathologies. The ADA and DPP-IV enzymatic
activities (expressed in IU L21) and soluble CD26 concentration
(expressed in mg L21) were determined in PE samples from 138,
147 and 159 patients, respectively. Gender and age factors were
considered in a basic demographic study as they affect DPP-IV
enzymatic activity and sCD26 concentration in serum4 and also
because TPE is generally diagnosed in younger patients and MPE
in older patients.
The mean ADA activity of the BPE group was 63.7 6 106.1 UL21
(Tables 2 and 3, and Figure 1). The mean value for the TPE group was
75.3 6 21.4 UL21, range 11.9–905.9. The high SD associated with the
mean value for the BPE group was due to cases of parapneumonic PE,
some associated with high ADA values. The values were much higher
than in other BPE and MPE groups (except for one lymphoma sam-
ple), as expected (Fig. 1). Almost half of the TPE patients were less
than 36 years old, in contrast to the other groups (Table 2). However,
although with a few cases, the ADA activity was higher in older than
in young individuals only in the parapneumonic group (Table 2).
Further studies are required to confirm the trend towards higher
levels of activity in women.
The DPP-IV activity was lowest in the TPE group (mean 36.8 6
12.1 UL21, range 38.3–127.6: Table 2 and 3, and Figure 1), for 41.8 6
24.0 UL21 in total BPE, but only mesotheliomas (60.5 6 37.0) and
lymphomas (116.3 6 10.7) MPE groups were significantly different
(Table 2). Although not statistically significant, there was a trend
towards lower DPP-IV activity in the older patients (see BPE and
MPE means, Table 2).
The commercial ELISA (Bender MedSystems) used in the present
study was the same as used in other studies, and therefore compar-
ison of the serum sCD26 levels is easier1. The mean concentrations of
sCD26 measured in BPE and MPE were 360.8 6 136.1 mg L21 (range
92.31–687.92 mg L21) and 392.8 6 352.4 mg L21 (range 62.6 – 2
256.54 mg L21) respectively (Table 1 and 2). The results were similar
to those obtained for carcinomatous pleurisy in a study using the
same kit18 and to those obtained with a different kit20. However, the
present study included a larger number of patients, and the mean
concentration of sCD26 in TPE was not only similar to that of BPE
but also to those of total MPE and MPE groups (Tables 2 and 3). High
values of sCD26 were only observed in paramalignant PEs in the BPE
group and particularly mesotheliomas and one lymphoma in MPE.
Taking age into account, we found that the concentrations of sCD26
were significant lower in older ($56) than in younger patients
(Table 3).
No differences were found for the other epidemiological factors
studied, such as smoking habit, cytology and neoplasic history.
Diagnostic value of determining ADA and DPP-IV activity and
sCD26 concentration in samples of benign and malignant PE. For
TPE diagnosis with the ADA activity test, a cut-off value of 40 UL21
was chosen as this is commonly used in the clinical setting. For
DPP-IV and sCD26, ROC curves that best distinguished TPE and
Figure 1 | Levels of (A) ADA enzymatic activity, (B) DPP-IV enzymatic activity and (C) sCD26 concentration in pleural effusion (PE) samples from
patients diagnosed with the following types of PE, from left to right: benign PE (circles), including tuberculous, parapneumonic, paramalignant,
non neoplasic and miscellaneous PE; malignant PE (triangles), including epithelial, mesothelioma and lymphoma PE.
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non-neoplasic BPE groups from the other groups were constructed.
The cut-off value of 61 UL21 obtained for the DPP-IV activity was
adjusted to 60. For the sCD26 levels, the cut-off obtained was not
useful and therefore the mean value plus the standard deviation, a
cut-off of 470 mg L21, was used.
Thus, only 1 of 30 cases of TPE (in a middle-aged patient) was
found to be negative for ADA (value below the cut-off). The ADA
levels were lower in this age group than in the other groups (Table 3).
The main problem associated with the use of ADA activity to dia-
gnose TPE was that another 8 of 51 non-tuberculous BPE (5/21
parapneumonic PE patients) were also positive, as well as three (3/
57) MPE (Table 4), i.e. this biomarker shows poorer specificity
(89.8%) than sensitivity (96.7%) in clinical diagnosis.
According to these data, determination of DPP-IV activity and
sCD26 concentration will not enhance the sensitivity of TPE detec-
tion since only 1 and 4 out of 30 patients were found to be positive,
and the negative ADA case was also negative for both biomarkers. In
fact, many more cases were found to positive for these markers,
particularly DPP-IV, in the other BPE and MPE groups (Table 4).
Fischer’s exact test for the contingency tables showed that all groups
except the paramalignant group were statistically significantly dif-
ferent from the TPE group for DPP-IV (p 5 0.002 for TPE compared
with the other groups), whereas the sCD26 levels only differed in
mesothelioma and lymphoma PEs.
However, DPP-IV and sCD26 may enhance the specificity of the
ADA test for TPE detection, i.e. detection of false TPE positive
results. From the group of 11 false positives, 3/5 of ADA1 parapneu-
monic patients were also DPP-IV1 and a fourth was close to the cut-
off (the other BPE cases were negative for DPP-IV) (Table 3) and the
three MPE ADA1 cases were also positive for the other two mea-
sures. Calculation of the Net Reclassification Improvement (NRI)
showed that of the 12 wrongly classified cases (11 false positives
and one false negative: 8.7%), 6 false positives (4.3%) could be reclas-
sified, with an NRI of 4.4% (95% CI 2.3–6.5% and p 5 0.031, see
Methods). Important for the patient, the ones remaining wrongly
classified have not a malignant pathology.
We used exploratory NRI with more cut-off values per biomarker
(continuous NRI), to develop a model that could improve diagnosis
of other PE groups, but we did not find any values of clinical interest.
However, an important number of the MPE samples were ADA
negative and DPP-IV (18/60) and sCD26 (13/67) positive: these were
mainly from patients with lymphomas and mesotheliomas, but also
epithelial MPE (14/54 for DPP-IV compared with 0/50 for ADA)
(Table 4). As 11/81 BPE were also ADA- DPP-IV1, these biomar-
kers are not useful for MPE diagnosis in their present form. However,
we did not observe any relationship between these frequencies in
epithelial MPE and any other pathological condition. Also, 11/40
cases of non-small cell lung cancer (NSCLC) were positive for
DPP-IV, compared with 7/42 cases for sCD26; by contrast, more
sCD261 than DPP-IV1 cases were detected in the mesothelioma
group (Table 3).
Correlations between DPP-IV activity, sCD26 concentration,
standard biochemical parameters and cell counts, in samples of
benign and malignant PE. The DPP-IV and sCD26 biomarkers did
not perform in the same way in the different groups of patients
(Table 4). Also, some data were lost due to technical problems
with the measurement of enzymatic activity. Thus, we tried to
obtain further information that could enhance the value of these
biomarkers.
Since serum DPP-IV activity and sCD26 concentration are not
always correlated1, the correlation values in PE were analysed for the
different groups of patients. The DPP-IV activity and sCD26 values
were correlated in both the BPE group (Spearman’s R 5 0.34 and p 5
0.001) and MPE group (Spearman’s R 5 0.433 and p , 0.001)
(Table 5 and Fig. 2). The DPP-IV activity and sCD26 values in the
TPE sub-group and in the epithelial MPE sub-group (with higher
enzymatic activity) were also correlated (Spearman R 5 0.69, p ,
0.001; and R 5 0.44, p 5 0.001, respectively). We conclude that the
values of both biomarkers in PE are generally specific to the sCD26/
DPP-IV protein. Interestingly, in the other sub-groups in which the
correlations could be determined, mesotheliomas in MPE and para-
pneumonia and miscellaneous in BPE, the correlation was totally
absent, except in non-neoplasic BPE (Table 5). An additional pattern
related to that protein therefore appeared in these pathological
conditions.
A significant correlation between ADA and sCD26 was also
detected in the MPE samples (R 5 0.3, p 5 0.023), probably due
Table 1 | Demographic data for the population under study
Aetiology of PE No. of Patients No. of Men/Women Age, years Mean (Range)
BPE 93 64/29 55 (20–96)
Tuberculosis 30 20/10 44 (20–96)
Parapneumonic 29 22/7 55 (26–89)
Paramalignant 4 2/2 61 (40–81)
Non neoplastic of unknown origin 18 13/5 65 (37–87)
Miscellaneous 12 7/5 62 (24–94)
After surgery 3 2/1 64 (53–74)
Chylothorax 3 2/1 73 (54–94)
Secondary to collagen vascular diseases 3 1/2 47 (37–59)
Secondary to drug reaction 1 1/0 24
Dressler’s Syndrome 1 1/0 80
After trauma 1 0/1 83
MPE 67 42/25 67 (20–91)
Epithelial origin neoplasias 58 34/24 68 (34–91)
NSCLC 42 30/12 68 (37–91)
Breast cancer 6 0/6 63 (34–75)
SCLC 3 3/0 72 (57–81)
Ovarian cancer 2 0/2 82 (79–85)
Thymic epithelial neoplasm 2 0/2 69 (65–73)
Gastric cancer 2 0/2 73 (60–83)
Cholangiocarcinoma 1 1/0 61
Mesothelioma 6 5/1 67 (57–87)
Lymphoma 3 3/0 55 (20–79)
Abbreviations: MPE, malignant pleural effusion; BPE, benign pleural effusion.
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to the high coefficient (Pearson’s) obtained for mesotheliomas,
although no such correlation was observed in epithelial MPE samples
(Table 5). No correlation between these parameters was found in
BPE, as well (Table 5). A correlation between DPP-IV and ADA
activity was observed in patients grouped as MPE or BPE
(Pearson’s test, data not shown), but when the different sub-types
were analysed separately, a correlation (Spearman’s test) was only
found in patients with parapneumonic PE (Table 5). These findings
confirm a biological relationship between these two proteins,
although the type of relationship will depend on the aetiology of
the PE.
We also compared our data with the standard values of biochem-
ical parameters and cell counts. With respect to biochemical para-
meters, the most consistent finding was that LDH levels and total
protein concentration were significantly correlated with sCD26,
ADA and DPP-IV in MPE and BPE (with the following exceptions:
LDH and sCD26 in BPE, and total protein concentration and DPP-
IV or ADA in MPE (data not shown). ADA and DPP-IV (and sCD26
nearly significant) were negatively correlated with glucose and pH
only in BPE (data not shown).
With respect to cell counts, ADA was correlated (Spearman test)
with the number of MC in both BPE (R 5 0.329; p 5 0.003) and MPE
(R 5 0.264; p 5 0.047)( Fig. 2C, upper dots), as well as with the
number of PMN (Pearson R 5 0.604; p , 0.001 in BPE, and R 5
0.315; p 5 0.018 in MPE), as expected. However, while DPP-IV
activity was significantly correlated with the number of PMN (R 5
0.351; p 5 0.001) and almost correlated with the number of MC (R 5
0.191; p 5 0.077) in BPE, and it was correlated with the number of
MC in MPE (R 5 0.257; p 5 0.049) (Fig. 2C, low left dot), sCD26
concentration was not correlated with the cell count (data not shown
and Fig. 2C bottom right).
Pleural effusion sCD26 immunoblot. As mentioned before, in the
mesothelioma group, unlike in epithelial MPE, we detected more
sCD261 cases than DPP-IV1 cases. Furthermore, in mesothe-
lioma MPE and pneumonic and miscellaneous BPE, there was a
total lack of correlation between CD26 and DPP-IV; finally, DPP-
IV activity (but not sCD26 concentration) was significantly corre-
lated with the number of leukocytes. Thus, we analysed samples from
patients of different pathologies with disparate or uncorrelated
values for sCD26 and DPP-IV by western blotting to try to obtain
biochemical information to explain the above results.
The TP1/16 anti-CD26 mAb was characterized in immunoblots of
cell lysates under partially denaturing conditions so that it could be
compared with other known anti-CD26 mAb, which only work
under such conditions25,26. In serum, a region of three diffuse bands
of between 125 and 135 kDa was observed (data not published), as in
cell lysates, plus a band of around 180 kDa and an additional region
of three diffuse bands of between 80 and 90 kDa. These MW are very
similar to the monomer of 727 aa of sCD26 (D39-766 of PM CD26)
Table 2 | ADA and DPP-IV activity and sCD26 concentration in PE according to gender groups in the study population (mean 6 SD)
All Men Women
ADA activity (UL21) Total 56.2 6 135.9 (138) 55.1 6 140.1 (91) 58.3 6 129.0 (47)
BPE 63.7 6 106.1 (81) 50.5 6 48.2 (57) 91.1 6 171.8 (24)
1TPE 75.3 6 21.4 (30){ 69.5 6 15.1 (20) 86.9 6 27.7 (10)
1pneumonic* 90.4 6 200.1 (21){ 53.6 6 78.8 (17) 246.7 6 439.9 (4)
1paramalignant 30.7 6 4.1 (3) 29.0 6 4.0 (2) 34.2 6 0 (1)
1non neoplastic 37.1 6 42.8 (15) 25.8 6 9.4 (11) 53.9 6 66.6 (4)
1miscellaneous 26.5 6 14.0 (12) 22.8 6 6.2 (7) 32.8 6 22.2 (5)
MPE 46.1 6 168.5 (57)‘ 62.0 6 215.3 (34) 21.1 6 6.1 (23)
1epithelial 22.7 6 7.2 (50)I 24.06 7.8 (28) 21.1 6 6.2 (22)
1mesothelioma 34.4 6 19.1 (5) 37.6 6 20.4 (4) 21.5 6 0 (1)
1lymphoma 686.8 6 889.8 (2) 686.8 6 889.8 (2) 0
DPP-IV activity (UL21) Total 45.4 6 27.19 (140) 47.9 6 28.4 (89) 42.0 6 25.8 (51)
BPE 41.9 6 24.0 (80) 42.9 6 23.1 (53) 41.0 6 27.1 (27)
1TPE 36.8 6 12.1 (30) 37.3 6 12.9 (20) 35.8 6 10.9 (10)
1pneumonic* 45.3 6 25.5 (29) 48.2 6 26.4 (22) 36.1 6 21.6 (7)
1paramalignant 45.7 6 17.3 (2) 33.5 6 0 (1) 57.9 6 0 (1)
1non neoplastic 40.9 6 26.7 (10) 39.6 6 30.8 (5) 45.8 6 35.9 (5)
1miscellaneous 49.4 6 41.2 (9) 47.2 6 34.4 (5) 52.1 6 54.1 (4)
MPE 50.5 6 30.8 (60) 55.4 6 33.6 (36) 43.1 6 24.9 (24)
1epithelial 47.3 6 27.7 (54)1 50.0 6 29.5 (31)1 43.6 6 25.3 (23)
1mesothelioma 60.5 6 37.0 (4) 70.1 6 46.8 (3) 31.7 6 0 (1)
1lymphoma 116.3 6 10.7 (2) 116.3 6 10.7 (2) 0
sCD26 concentration (mg L21) Total 337.5 6 253.1 (159) 388.5 6 286.4 (106) 355.2 6 165.8 (53)
BPE 360.8 6 136.1 (92) 356.1 6 128.3 (64) 371.8 6 154.1 (28)
1TPE 367.1 6 113.4 (30) 357.5 6 107.7 (20) 386.4 6 127.8 (10)
1pneumonic* 363.1 6 143.3 (29) 391.2 6 119.1 (22) 274.5 6 184.7 (7)
1paramalignant 456.7 6 176.1 (4) 422.0 6 295.6 (2) 491.4 6 27.2 (2)
1non neoplastic 362.5 6 151.5 (18) 336.6 6 142.9 (13) 429.8 6 168.4 (5)
1miscellaneous 300.4 6 132.2 (11) 258.9 6 115.6 (7) 373.1 6 143.2 (4)
MPE 392.8 6 352.4 (67) 426.3 6 421.9 (42) 336.6 6 179.4 (25)
1epithelial 332.8 6 173.1 (58) 328.6 6 168.6 (34) 338.9 6 182.9 (24)
1mesothelioma 990.6 6 897.6 (6)# 1132.4 6 925.5 (5) 281.8 6 0 (1)
1lymphoma 357.0 6 225.3 (3) 357.0 6 225.3 (3) 0
In parentheses (n) number of samples.
*, para and metapneumonic. Interesting statistically significant differences indicated: For ADA;
{U-Mann p , 0.001 between TPE and other groups, except pneumonic PE;
{U-Mann p , 0.001 between pneumonic PE and other groups except TPE;
‘, T-student p , 0.001 between BPE and MPE;
I, Kruskal-Wallis ANOVA p , 0.001 for MPE groups. For DPP-IV;
1, U-Mann p 5 0.022 (total) and p 5 0.029 (men) between MPE epithelial and lymphoma. For CD26;
#, Kruskal-Wallis p , 0.001 for mesotheliomas compared with the other groups.
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with different degrees of glycosylation (80–90 kDa), plus the addi-
tional presence of one ADA molecule (around 42 kDa)-CD26 inter-
action (as already mentioned, CD26 was first identified as ADA
binding or complexing protein)1–4,12,27.
In PE (Fig. 3A), under the same partially denaturing conditions,
staining in the 125–135 kDa region was very slight or was absent in
the samples analysed and the major bands were around 80–90 kDa.
It can be deduced that the sCD26 in PE was mainly free of ADA (of
the ADA-1 isoform). In addition, under denaturing conditions, the
anti-CD26 mAb was able to stain bands of 60 kDa (37uC) or 45 kDa
(100uC) (Fig. 3A), which may correspond to the same protein lacking
a glycosylated epitope.
The main finding (Fig. 3B) was that the 180 kDa band detected in
serum under the partially denaturing conditions was present in most
of the MPE samples and absent or fainter in most of the BPE samples.
Because of the potential diagnostic value, we analysed the band by
Mass Spectrometry (MS/MS) in triplicate experiments. We identified
fibrinogen alpha, beta and gamma chains, and alpha-2 macroglobu-
lin proteins, but not sCD26.
Discussion
We observed lower levels of DPP-IV enzymatic activity in TPE
patients than in patients with other benign or malignant PE and
similar levels of sCD26 in all types of patients. This contrasts with
previous reports of significant increases in DPP-IV activity19 and
sCD26 levels18,20 in TPE. Although the sCD26 levels we observed
in TPE were similar to those reported by Wang et al20, these authors
used a different type of control group (fewer patients and patholo-
gies) than in the present study. We also found low levels of sCD26 in
epithelial MPE (although not as low as in Wang’s study); however,
many patients had high levels of sCD26 in the MPE group. We did
not find any epidemiological factor or anatomopathological data that
discriminated epithelial MPE sub-groups according to sCD26 levels.
In comparison with a study with fewer patients, Oshikawa and
Sugiyama18 found that some TPE patients had very high sCD26
levels, but this was not repeated in our data.
These results for sCD26 were confirmed by the similar data for the
DPP-IV activity measured in parallel in our study. The DPP-IV
activity levels were similar to those observed by Küpeli et al in
TPE19. However, we found that the activity of this enzyme was higher
in pneumonic BPE and MPE than in TPE. These differences may be
due to the larger number of patients examined in our study.
We found that use of sCD26/DPP-IV as biomarkers did not
improve the sensitivity of TPE diagnosis. However, measurement
of DPP-IV may improve the specificity of TPE diagnosis because,
when the ROC curve that best differentiated tuberculous plus non-
neoplasic PE groups from the other groups was done, yielding a cut-
off value of 60 UL21, 6 out of 11 false positive TPE (ADA positive in
other non-TPE groups) were also DPP-IV positive. Interestingly
because of the lack of biomarkers for MPE, a relatively large number
of MPE were ADA negative and sCD26 positive (in particular DPP-
IV). However, there were no specific clinical data that might be
associated to these cases, and some BPE cases would be classified
as positive for this combination of the biomarkers.
Table 3 | ADA and DPP-IV activity and sCD26 concentration in PE according to age groups in the study population (mean 6 SD)
#35 years old 36–55 years old $56 years old
ADA activity (UL21) Total 131.3 6 288.4 (19) 43.9 6 57.4 (32) 45.1 6 98.4 (86)
BPE 68.0 6 28.9 (17) 50.2 6 65.2 (24) 70.1 6 142.6 (39)
1TPE 78.4 6 19.1 (14) 63.6 6 15.6 (7) 79.5 6 27.1 (9)
1pneumonic* 18.7 6 7.6 (2) 73.7 6 130.1 (6) 109.1 6 241.5 (13)
1paramalignant 0 29.0 6 4.0 (2) 34.2 6 0 (1)
1non neoplastic 0 26.1 6 12.6 (5) 42.6 6 51.8 (10)
1miscellaneous 21.1 6 0 (1) 32.0 6 22.5 (4) 23.7 6 7.0 (6)
MPE 669.5 6 914.4 (2) 25.1 6 8.7 (8) 24.3 6 10.6 (47)
1epithelial 22.9 6 0 (1) 25.1 6 8.7 (8) 22.2 6 7.0 (41)
1mesothelioma 0 0 34.4 6 19.1 (5)
1lymphoma 1316.0 6 0 (1) 0 57.7 6 0 (1)
DPP-IV activity (UL21) Total 43.7 6 20.9 (21){ 51.1 6 26.2 (35){ 43.6 6 28.8 (91)
BPE 41.0 6 15.2 (19) 47.1 6 25.2 (26) 39.2 6 26.3 (42)
1TPE 39.8 6 10.4 (14) 38.3 6 17.7 (7) 31.1 6 8.0 (9)
1pneumonic* 33.0 6 5.0 (4) 50.8 6 26.1 (10) 44.9 6 28.2 (15)
1paramalignant 0 57.9 6 0 (1) 33.5 6 0 (1)
1non neoplastic 0 57.2 6 40.7 (6) 32.0 6 19.1 (11)
1miscellaneous 90.1 6 0 (1) 23.0 6 4.1 (2) 51.3 6 45.8 (6)
MPE 69.6 6 55.3 (2)‘ 62.8 6 26.8 (9)‘ 47.4 6 30.5 (49)‘
1epithelial 30.5 6 0 (1) 62.8 6 26.8 (9) 44.5 6 27.4 (44)
1mesothelioma 0 0 60.5 6 42.7 (4)
1lymphoma 108.7 6 0 (1) 0 123.8 6 0 (1)
sCD26 concentration (mg L21) Total 389.1 6 128.6 (21) 412.3 6 148.2 (37){ 357.4 6 295.1 (101){
BPE 379.6 6 123.5 (19) 392.2 6 158.3 (28)1 322.5 6 136.3 (45)1
1TPE 379.3 6 112.3 (14) 353.1 6 60.6 (7) 359.1 6 151.2 (9)
1pneumonic* 367.3 6 189.0 (4) 377.4 6 149.8 (10) 352.3 6 136.8 (15)
1paramalignant 0 491.4 6 27.2 (2) 422.0 6 295.6 (2)
1non neoplastic 0 500.5 6 134.0 (6) 293.5 6 108.2 (12)
1miscellaneous 432.9 6 0 (1) 414.4 6 144.0 (3) 232.6 6 86.4 (7)
MPE 479.3 6 195.0 (2) 420.1 6 205.7 (9) 385.4 6 376.4 (56)
1epithelial 341.4 6 0 (1) 420.1 6 205.7 (9) 316.3 6 165.6 (48)
1mesothelioma 0 0 990.6 6 897.6 (6)
1lymphoma 617.2 60 (1) 0 226.9 6 2.4 (2)
In parentheses (n) number of samples. Significant differences between age groups: For DPP-IV;
{U-Mann p 5 0.007;
‘p 5 0.013 and p 5 0.003 respectively. For sCD26;
{p , 0.001 and
1p 5 0.007.
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Statistical analysis of the data on these biomarkers and ADA
revealed that the sCD26 concentration and ADA activity were cor-
related in the mesothelioma MPE group but not in the other PE
groups. This was probably because of changes in the presence of
ADA2 isoform, which does not bind to sCD26 but is abundant in
PE6,7,10 (we did not find the ADA1 isoform bound to sCD26 in the
immunoblots). This suggests that analysis of ADA isoforms could
help enhance the specificity of TPE diagnosis28. Similarly, DPP-IV
and ADA activities were correlated in patients grouped as MPE and
BPE, but not in patients grouped according to aetiology, except in
patients with parapneumonic PE.
Analysis of biomarkers in relation to the cell count revealed a
strong correlation between ADA and the number of leukocytes in
both BPE and MPE groups, whereas sCD26 was not correlated with
the cell count. Although ADA2 is derived from the monocyte frac-
tion, the origin of sCD26/DPP-IV is more controversial. It has been
suggested that serum sCD26 may originate from liver, endothelial
capillary cells and immune cells (mainly T, cells)1. From our data, we
conclude that only a minor fraction, if any, of sCD26 from PE (both
MPE and BPE) originated from immune cells. In the lung, apart from
capillaries, DPP IV has also been demonstrated in the submucosal
serous glands and the alveolar cells4. However, the significant
correlation between DPP-IV activity (but not sCD26) and leukocyte
number (mainly MC) in both BPE and MPE groups indicates that a
fraction of this activity is indeed derived from lymphocytes.
Serum DPP-IV enzymatic activity and sCD26 concentration are
not closely correlated in patients of certain diseases and even in
healthy donors, for at least three reasons1: i) some circulating
proteins other than sCD26 display DPP-IV activity29; ii) hypersialy-
lation (which is strongly enhanced in elderly individuals) of sCD26
can inhibit DPP-IV activity; and iii) the serum protein attractin
may regulate the DPP-IV activity of CD2630–32 Interestingly, the
performance of sCD26/DPP-IV as biomarkers was also different in
PE samples. Although DPP-IV activity and sCD26 concentration
were strongly correlated, confirming that most of the data above
are specific for the sCD26/DPP-IV protein, the correlation was
totally absent in some PE subgroups (mesotheliomas in MPE, and
pneumonic and miscellaneous in BPE), indicating that one of the
above-mentioned patterns probably occurred in these pathological
conditions.
Like the anti-CD26 mAb used in the present study, in samples of
serum the 1F7 anti-CD26 mAb detected by western blot a band of
180 kDa which was originally described as DPPT-L30,31, a protein
originated in T cells with DPP-IV activity. The band has recently








Total n 1n % Total n 1n % Total n 1n %
BPE 81 36 44.4 80 15 18.8 92 14 15.2
1TPE 30 29 96.7 30 1 3.3 30 4 13.3
1pneumonic 21 5 23.8 29 8 27.6 29 5 17.2
1paramalignant 3 0 0 2 0 0 4 1 25.0
1non neoplastic 15 2 13.3 10 3 30.0 18 3 16.7
1miscellaneous 12 1 8.3 9 3 33.3 11 1 9.1
MPE 57 3 5.3 60 18 30.0 67 13 19.4
1epithelial 50 0 0 54 14 25.9 58 8 13.8
1mesothelioma 5 1 20.0 5 3 60.0 6 4 66.7
1lymphoma 2 2 100.0 2 2 100.0 3 1 33.3
Positive results for ADA, sCD26 and DPP-IV activity (1) represent all cases above the cut-off values of 40 and (60) U L21 and 470 mg L21, respectively. Frequencies shown in shaded type indicate significant
differences from the TPE group, as revealed by Fischer’s exact tests done with contingency tables.
Table 5 | Correlations between ADA and DPP-IV activity and sCD26 concentration in PE according to the groups under study
n R- Pearson P- Pearson R-Spearman P-Spearman
BPE: TPE sCD26 vs ADA 30 - - 0.230 0.222
sCD26 vs DPP-IV 30 - - 0.689 0.000
ADA vs DPP-IV 30 0.039 0.839 - -
BPE: Pneumonic sCD26 vs ADA 21 - - 20.331 0.143
sCD26 vs DPP-IV 29 - - 0.008 0.968
ADA vs DPP-IV 21 - - 0.466 0.033
BPE: Miscellaneous sCD26 vs ADA 10 - - 0.224 0.533
sCD26 vs DPP-IV 9 - - 0.067 0.865
ADA vs DPP-IV 8 20.209 0.619 - -
BPE: Non neoplasic sCD26 vs ADA 15 - - 20.196 0.483
sCD26 vs DPP-IV 17 0.796 0.000 - -
ADA vs DPP-IV 14 - - 20.323 0.260
MPE: Epithelial sCD26 vs ADA 50 0.217 0.130 - -
sCD26 vs DPP-IV 54 - - 0.444 0.001
ADA vs DPP-IV 48 - - 0.115 0.437
MPE: mesothelioma sCD26 vs ADA 5 0.988 0.001 - -
sCD26 vs DPP-IV 4 - - 0.400 0.600
ADA vs DPP-IV 3 - - 0.500 0.667
n: Number of samples analysed, with statistically significant differences shown in bold type. Pearson’s analysis was used for normally distributed samples, and Spearman’s analyses was used for non-
normally distributed samples.
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been identified as the protein attractin strongly bound to sCD2629,32.
In this study, the TP1/16 anti-CD26 mAb identified a 180 kDa band,
which was more abundant in those pathologies in which the correla-
tions were absent, and in which DPP-IV was associated with mono-
nuclear cells.
However, analysis of the band by MS revealed alpha, beta and
gamma chains of fibrinogen and alpha-2 macroglobulin proteins,
but not sCD26. These proteins have been found in PE33,34 and may
mask sCD26-attractin. However, further study is warranted by pre-
vious findings that CD26/DPP-IV acts as receptor for plasminogen
type 235,36 and that alpha-2-macroglobulin inactivates serine-prote-
ases and also inhibits fibrinolysis via inhibition of plasmin37.
Methods
Patients. Patients (n 5 159) admitted between April 2007 and December 2010 to the
Unit of Interventional Bronchopleural Pathology, of the Pneumology Service of
Complejo Hospitalario Universitario de Vigo (CHUVI) with a specific diagnosis for
exudative PE were consecutively enrolled in this study.
All procedures followed the clinical-ethical practices of the Spanish Government;
the protocol of the study was approved by the Galician Ethical Committee for Clinical
Research (2007/179), and complied with the Helsinki Declaration, Oviedo Agreement,
the Organic Law for Data Protection 15/1999 and Royal Decree 1720/2007. Informed
consent was obtained from all subjects.
Sample diagnosis. As described in previous studies38,39, initial diagnostic
thoracocentesis for biochemical, microbiological and cytological studies was
performed in all patients. If a diagnosis was not obtained after this test in patients with
exudative PE, a second thoracocentesis and a blind percutaneous pleural biopsy with
an Abrams needle were carried out. In some patients in whom PE was still not
identified, thoracoscopy was conducted. The following biochemical parameters and
cell counts in pleural fluid were determined before any therapy was started: pH,
protein concentration, glucose and LDH levels, and the number of leukocytes and
percentage of mononuclear (MC) and polymorphonuclear (PMN) cells.
The aetiology of PE was based on accepted criteria, as described by the Spanish
Society for Pneumology and Thoracic Surgery40 and the British Thoracic Society
guidelines41. Benign PE (BPE) was divided into five groups: tuberculous, parapneu-
monic, miscellaneous, paramalignant and non-neoplasic of unknown origin,
according to recently reported diagnositc measures39,42. Malignant PE (MPE)
included PE in which malignant cells were demonstrated at cytological or histological
examination or in a biopsy specimen. MPE was divided into three subgroups
according to the aetiology of the PE: epithelial-origin neoplasia, mesothelioma and
lymphoma. Patients who were not classified in any of these diagnostic groups were
excluded from the study.
Sample collection. Approximately 10 mL of PE sample was obtained with a needle at
the same time as thoracocentesis and pleural biopsy. Samples were centrifuged at
800 g for 15 minutes, and frozen in 0.5 aliquots at 220uC until the measurements
were performed.
Enzyme assays. Abnormal values were obtained for haemolytic and turbid samples.
These values were excluded from data analysis.
The ADA was determined by an automated test carried out in a Unicel DXC 600i
Syncron (Beckman Coulter). The measurement was based on the colorimetric kin-
etics of ADA catalytic activity whereby adenosine is transformed to inosine and
ammonia, and the ammonia then reacts with sodium hypochlorite and phenol at
37uC to form indophenol, which yields an intense blue colour. The indophenol was
measured spectrophotometrically at 630 nm. The results are expressed in UL21.
DPP-IV activity was measured in 96-well culture plates with Gly-Pro-p-nitroani-
lide (0.2 mM, Sigma) as substrate in reaction mixtures (100 mL) containing PF
samples (10 mL) and 50 mM Tris-HCl, pH 8.015. After incubation of the plates for
15 min, substrate hydrolysis was monitored at a wavelength of 405 nm in a BioRad
Model 680 microplate reader. The results were determined by comparison with a
standard curve for p-nitroaniline (Sigma data sheet) and the activity is expressed as
UL21. All experiments were performed in duplicate, unless otherwise specified.
Determination of the sCD26 levels. The sCD26 concentration was measured with
the sCD26 ELISA kit (Bender Medsystems; Vienna, Austria) according to the
manufacturer’s instructions1,13. Colorimetric quantification was performed with a
microplate reader (model 550; Bio-Rad, USA) at 450/630 nm.
Figure 2 | Correlations between (A) sCD26 concentration and DPP-IV
activity, and (B) ADA activity and sCD26 concentration, in some types of
PE. Spearman’s correlation coefficient (R) and p values are shown on the
graphs; (C) Correlation between these biomarkers and the MC counts in
BPE or MPE groups.
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Immunoblotting of soluble CD26. First, the amount of protein in the PE was
quantified by the Bradford protein assay (Biorad, CA, USA). Samples containing
20 mg of protein were then subjected to 7.5% SDS-PAGE under non-totally reducing
(samples with b-mercaptoethanol incubated at 37uC for 15 min) conditions and
electroblotted onto PVDF membranes (Millipore, Bedford, MA, USA). Blots were
treated with 5% skimmed milk blocking buffer (TBS 1% Tween-20) and were
incubated overnight at 4uC. After three washes with TBS-Tween buffer, the
membranes were incubated for 1 h at room temperature with anti-human CD26
mAb (clone TP1/16). The TP1/16 anti-CD26 antibody was previously characterized25
in immunoblots of cell lysates under partially denaturing conditions so that it could
be compared with the better-known anti-CD26 1F7 mAb, both of which perform
considerably better than other antibodies used in several immune techniques26. Goat
anti-mouse IgG-HRP conjugated secondary antibody Fc-Specific (Sigma Aldrich)
and Precision Plus Protein, Western C Standards (Bio Rad, USA) was used for protein
detection before membranes were exposed a few minutes to ECL Prime Western
Blotting Reagents substrate solution (GE, Amersham, UK) under appropriate dark
room conditions. Results were analysed with ChemiDoc XRS (BioRad) software.
Protein identification by mass spectrometry. In parallel to the above-described
immunoblot, a band of 180 kDa was excised from a replicate gel and digested with
12.5 ng/mL of trypsin (Roche Molecular Biochemicals) in 25 mM ammonium
bicarbonate (pH 8.5) overnight at 37uC43. The supernatant was then collected and
1 mL was spotted onto a MALDI target plate and allowed to air-dry at RT. Then,
0.4 mL of a-cyano-4-hydroxy-cinnamic acid matrix (3 mg/mL) (Sigma) in 50% (v/v)
ACN was added to the dried peptide digest spots and allowed to air-dry at RT.
MALDI-TOF MS analysis (4800 Proteomics Analyzer MALDI-TOF/TOF mass
spectrometer (Applied Biosystems) was performed by the Proteomics Service,
University of Vigo. Mass spectra were calibrated with internal peptides from trypsin
autodigestion. A database search was performed with MASCOT Daemon search
engine 2.1 (Matrix Science) through the Global Protein Server version 3.6 (Applied
Biosystems) against SwissProt 2012_07 (536789 sequences; 190518892 residues), as
previously described43.
Statistical analysis. Statistical analysis was performed with the SPSS package (v16.0).
Two tailed tests were carried out, and differences were considered significant at p ,
0.05. Normal distributions and homogeneity of variances were verified by
Kolmogorov-Smirnov and Mann-Whitney U tests respectively. Data from the three
measures combined, alone, or grouped according to the pathological condition were
not always normally distributed (shown when necessary).
The Mann-Whitney U test was used for analysis of two independent samples, and
the Kruskal-Wallis ANOVA was used for more than two samples. Fischer’s exact tests
for contingency tables were used for analyses regarding positivity/negativity of the
sCD26. Correlations between parameters were evaluated by parametric and non-
parametric tests according to their distribution. Differences were considered sig-
nificant at p , 0.05.
For ROC curve analysis of ADA, sCD26 and DPP-IV values, cut-offs points were
generated with MedCalc, version 11.5.1 (MedCalc Software, Belgium). We selected
the cut-off values with the highest value for the combined sensitivity and specificity
for TPE detection as a proxy for the optimal cut-off value. For ADA, the cut-off
obtained was close to 40 UL21, i.e. the value used in the clinical setting. However, for
sCD26, a cut-off corresponding to the mean value plus the standard deviation of the
TPE group, performed better.
Net Reclassification Improvement (NRI) is an intuitive and easy to interpret
measure for evaluation of potential added value of new diagnostic instruments or
biomarkers in daily clinical practice. We chose this model44 to measure the biomar-
kers in combination with the ADA test for the diagnosis of TPE, using the same cut-
off values obtained as explained above, i.e. category-based NRI. This enables the
standard clinical values of specificity and sensitivity to be maintained45. We also
calculated the NRI by testing a model with two or three cut-off values per variable
(category-free or continuous-NRI) to determine whether the biomarkers could dia-
gnose other non-TPE groups.
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43. Rodrı́guez-Piñeiro, A. M., Blanco-Prieto, S., Sánchez-Otero, N., Rodrı́guez-
Berrocal, F. J. & de la Cadena, M. P. On the identification of biomarkers for non-
small cell lung cancer in serum and pleural effusion. J. Proteomics 73, 1511–1522
(2010).
44. Pencina, M. J., D’Agostino, R. B. Sr., D’Agostino, R. B. Jr. & Vasan, R. S. Evaluating
the added predictive ability of a new marker: from area under the ROC curve to
reclassification and beyond. Stat. Med. 27, 157–172 (2008).
45. Richard, E., Schmand, B. A., Eikelenboom, P. & Van Gool, W. A. MRI and
cerebrospinal fluid biomarkers for predicting progression to Alzheimer’s disease
in patients with mild cognitive impairment: a diagnostic accuracy study. BMJ
Open 3, e002541, doi:10.1136/bmjopen-2012-002541 (2013).
Acknowledgments
This research was partially supported by grants PS09-00405 and Research Intensification
activity from the Fondo de Investigación Sanitaria (FIS) of the Instituto de Salud Carlos III
(Spain) and funding from Xunta de Galicia and FEDER (CN 2011/024). We are grateful to
the patients who participated and made the study possible. We particularly thank A.
Fernández, V. Leiro, C. Represas, and M. Núñez (Pneumology Department, CHUVI) for
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